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Abstract The pancreas is a site of origin of a diverse range
of benign and malignant tumours, and these are frequently
detected, diagnosed and staged with computed tomography
(CT). Knowledge of the typical appearance of these
neoplasms as well as the features of locoregional invasion
is fundamental for all general and abdominal radiologists.
This pictorial essay aims to outline the characteristic CT
appearances of the spectrum of pancreatic neoplasms, as
well as important demographic and clinical information that
aids diagnosis. The second article in this series addresses
common mimics of pancreatic neoplasia.
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Imaging technique
Imaging of the pancreas is typically achieved with dual- or
triple-phase acquisitions. Imaging is performed in the non-
contrast, arterial and delayed portal venous phases using
rapid contrast agent administration at 3–5 ml/s, preferably
delivered via a wide bore cannula. High-density oral
contrast agent interferes with the delineation of vessels
and it can also make appreciation of an arterially enhancing
lesion more difficult. Oral administration of 500–700 ml
water approximately 30 min before imaging time is a safe
and effective way to achieve distension of the upper
gastrointestinal tract [1]. Water acts as a negative contrast
agent, differentiating the duodenum from the adjacent
pancreatic head. Positive oral contrast agent may also be
administered as part of the imaging preparation 60 min
before imaging if lower abdominal and pelvic delineation
of bowel loops from adjacent structures is required. Post-
resection imaging may require a positive contrast agent to
differentiate bowel loops from fluid collections and to help
identify anastomotic leaks.
Pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma accounts for 90% of all
pancreatic neoplasms. Most of the patients are over 60 years
of age at diagnosis. It is a common malignancy in both men
and women and has a low 5-year survival rate [2],
reflecting the predominance of late diagnosis and low
resection rates at presentation. These tumours grow rapidly
and metastasise early and only 10-15% of patients have
tumours that are potentially resectable at diagnosis [3].
Presenting symptoms can include jaundice, weight loss and
abdominal pain. Risk factors include chronic pancreatitis,
diabetes mellitus and hereditary cancer syndromes. Given
the significant morbidity and mortality of this malignancy,
early detection and accurate determination of resectability
are of vital importance.
Ductal adenocarcinomas occur in the pancreatic head in
78%, with 11% involving the body and 11% in the tail [2].
The earliest consistent imaging finding is dilatation of the
main pancreatic duct [4]. Sixty percent of small adenocar-
cinomas show duct dilatation without a visible mass [4].
The combination of a dilated pancreatic duct with a dilated
common bile duct (‘double duct sign’) is highly suspicious
for a pancreatic head malignancy. The tumour itself tends to
be a hypodense mass that distorts the contour of the gland
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DOI 10.1007/s13244-011-0102-7(Fig. 1), although it may be isodense to pancreatic
parenchyma on a unenhanced study. Tumour margins are
best defined on the arterial phase, with maximum enhance-
ment of the normal pancreatic parenchyma compared with
the relatively poor or non-existent enhancement of the
tumour [5]. Adenocarcinomas may be cystic (Fig. 2). Post-
processing displays such as maximum intensity projection
(MIP) can help define arterial structures. Coronal oblique
display allows optimal depiction of the portal vein [6].
Other important diagnostic features include atrophy of the
pancreatic tissue proximal to the tumour and a local fibrotic
tissue response [7].
The portal venous phase of imaging more clearly defines
pancreatic duct dilatation, peripancreatic tissue involvement
and distant metastases [8]. Features that determine non-
resectability include extrapancreatic invasion of vessels,
perineural invasion, adjacent thrombosis of venous struc-
tures, such as the splenic vein, splenoportal confluence or the
extrahepatic main portal vein, regional lymph node disease
as well as omental and distant metastases. Lymphatic
invasion may be seen as reticular soft tissue densities or
cuff surrounding the extrapancreatic vessels [9], while
perineural invasion appears as soft tissue passing in
continuity from the primary tumour along the path of a
known neural plexus and is most frequently seen around the
superior mesenteric artery [10]. Limited invasion of the
superior mesenteric vein (SMV) without thrombosis may not
rule out resection and some institutions will resect tumours
with isolated involvement of the proximal portal vein [6].
Tumours with splenic vessel involvement may be resected
with additional en bloc splenectomy. Venous invasion is
often described in terms of circumferential contiguity of the
tumour with the vein. If more than 50% (180˚) of the SMVis
contacted then the tumour will not be resectable [11].
Identifying arterial involvement can be difficult, especially
in the presence of atherosclerotic disease. Direct visual-
isation of abrupt change in vessel calibre and associated soft
tissue must be considered in determining arterial invasion
[11]. Superior mesenteric artery (SMA) involvement will
render the tumour non-resectable (Fig. 3).
The following computed tomography (CT) signs of
vascular invasion all have specificities of over 90% for
Fig. 1 Arterial phase CT in a 78-year-old woman with a hypodense
adenocarcinoma (long arrow) in the pancreatic head and invasion of
peripancreatic fat (arrowhead)
Fig. 2 Mixed cystic and solid adenocarcinoma (long arrow) with
irregular soft tissue elements (arrowhead) with invasion of the spleen
(short arrow)
Fig. 3 Arterial phase CT showing a hypodense adenocarcinoma
(arrows) in a 64-year-old woman encasing the superior mesenteric
artery
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signs provide even greater specificity [12–14]: (1) vessel
embedded in tumour; (2) tumour contact with over 180° of
vessel circumference; (3) vascular irregularity; (4) vascular
stenosis or thrombosis.
A meta-analysis demonstrated that CT had a sensitivity
of 91% and a specificity of 85% for diagnosing pancreatic
adenocarcinoma outperforming magnetic resonance imag-
ing (MRI) [15]. CT has a sensitivity of 81% for determining
resectability and a specificity of 82% [15]. Other studies
show a negative predictive value for resectability of 100%
and a positive predictive value of 89% with no significant
difference between systems of different generations [16].
Differentiating post-operative inflammatory changes from
tumour recurrence can also be challenging and serial
imaging is frequently required [17].
Cystic neoplasms
Cystic pancreatic neoplasms range from benign to malignant,
and although they may have diagnostic features on CT, often
other techniques—such asultrasoundand MRI—are required
for further evaluation. It is important to differentiate cystic
neoplasm from non-neoplastic pancreatic cysts, which is
discussed further in Part 2 of this series. Overall, cystic
neoplasms of the pancreas are relatively uncommon, account-
ing for only 1% of all primary pancreatic neoplasms [18].
Serous cystic neoplasms
Previously referred to as serous cystadenomas, these
tumours are further divided into microcystic and macro-
cystic (oligocystic) subgroups based on macroscopic
variation.
Microcystic adenoma
Microcystic adenomas are rare benign pancreatic tumours that
a r em o r ec o m m o ni nf e m a l e sa n dt e n dt oo c c u ri nt h e7 t h
decade of life—therefore termed the ‘grandmother’ tumour
[18]. Despite the predilection for females, cases do occur in
males. This can be helpful in differentiating these lesions
from mucinous cystic neoplasms, as these almost never occur
in males [19]. Microcystic adenomas may be discovered
incidentally or present with non-specific abdominal symp-
toms such as nausea or abdominal pain.
The classic appearance of a microcystic adenoma is of a
large hypodense mass composed of a conglomerate of small
cysts, each not more than 2 cm in size. There are multiple
thin septations that are highly vascular and therefore
enhance on post-contrast-enhanced imaging (Fig. 4)[ 19].
This results in a ‘honeycombed’ appearance. The supplying
vessels to the mass are frequently enlarged [19]. Another
common feature is a central hyperdense scar that may
contain calcifications (Fig. 5)[ 18]. The density of the lesion
can vary with internal protein content from water density to
muscle equivalent density [20]. The hypervascularity of the
septae can also result in internal haemorrhage.
Microcystic adenomas occur slightly more commonly in
the pancreatic head and can be so large that they almost
completely replace the gland. They are differentiated from
ductal adenocarcinoma by their typically large size
(>10 cm), honeycombed appearance, hypervascularity and
central scar [19]. Serum tumour markers such as carcinoma
embryonic antigen (CEA) and carbohydrate antigen (CA)
19.9 are typically within the normal range in cystic
pancreatic neoplasms and elevation of these markers is
also useful in distinguishing these lesions from ductal
adenocarcinoma [18].
Macrocystic serous adenoma
Macrocystic serous adenomas are a variant of the micro-
cystic adenoma. They are always benign and are charac-
terised by unilocular or bilocular cysts that are greater than
2 cm in size. Similar to microcystic adenomas, there is a
female predominance and the tumours more frequently
occur in patients over 50 years of age. With large cystic
spaces, these tumours can be difficult to distinguish from
mucinous cystic neoplasms [21]. Generally, endoscopic
ultrasound evaluation and aspiration are required to
Fig. 4 Cystic lesion (arrow) in a 71-year-old woman with calcifica-
tion and fine septations. Shown to be a microcystic cystadenoma
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a mucinous aspirate.
Serous cystic neoplasms, in particular microcystic neo-
plasms, may present with symptoms of mass effect when large.
Complications include obstruction of the second part of the
duodenum and jaundice due to common bile duct obstruction.
In these cases, complete tumour resection is the aim of
management [18]. For asymptomatic lesions, management is
more controversial. Tumours greater than 4 cm in size are
thought more likely to grow and eventually cause symptoms
and this may be used as a criterion for prophylactic resection
[18]. Ultimately, this decision would involve a risk–benefit
analysis of the patient’s age and medical comorbidities, as
well as tumour size and location in the pancreas.
Mucinous cystic neoplasm
Mucinous cystic neoplasms are the most common cystic
neoplasm and occur almost exclusively in middle-aged
women, (the ‘mother’ tumour) [22]. These tumours are
potentially malignant (mucinous cystadenocarcinoma) and
surgical resection is therefore the mainstay of treatment [18].
Most are incidental findings with the remainder presenting
with non-specific abdominal symptoms including weight
loss in metastatic cases.
These lesions tend to occur in the body or tail of the
pancreas and appear as a unilocular or multilocular cyst,
round or lobular with a smooth external margin (Fig. 6)[ 18,
23]. Mucinous cystic neoplasms tend to be large and
Fig. 6 a Large macrocystic cystadenocarcinoma (long arrow)i na n
80-year-old man. Note the irregular soft tissue septations (short
arrow). Mass causes biliary obstruction with a distended gallbladder
(GB) and intrahepatic ducts (arrowhead). b Axial arterial phase CT of
a hypodense cystic mass (arrow) in the anterior pancreatic head in a
66 year old female shown to be a macrocystic cystadenoma
Fig. 5 a Arterial phase CT in a 67-year-old woman with a
heterogeneous soft tissue mass shown to be a microcystic cystade-
noma. It almost appears solid with some central fluid attenuation
elements. Note it displaces vessels at the periphery rather than
invading and obstructing. b Portal venous CT in the same patient.
Note eccentric central enhancing ‘scar’ (arrow)
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cases [22, 23], often with nodularity of the wall or septae
with papillary projections into the lumen [18]. The internal
Hounsfield density measurement depends on the proportion
of mucoid content and haemorrhagic fluid [23].
Compared with the serous cystic neoplasms, cyst fluid
CEAiselevatedinmucinouscystictumours andthe degreeof
elevation correlates with the diagnosis of mucinous cystade-
nocarcinoma or mucinous cystadenoma with malignant
potential [18]. Serum tumour markers CA 125 and CA 72–
4 are also suggestive of a malignant or pre-malignant lesion
[18].
Intraductal papillary mucinous neoplasm
Intraductal papillary mucinous neoplasm (IPMN) is a low-
grade malignancy that more frequently occurs in elderly
patients with a male predominance (the ‘grandfather’
tumour). The tumour arises from a proliferation of the
pancreatic ductal epithelium and may be predominantly
cystic or papillary in composition. There is resultant excess
mucin production and progressive dilatation of the main
pancreatic duct or cystic dilatation of the branch ducts.
These lesions frequently present with pancreatitis, abdom-
inal pain or jaundice [24].
The presence of multifocal pancreatic cysts, present in
72% of cases, supports the diagnosis of IPMN as multi-
focality is unusual in other cystic neoplasms [25]. The key
radiological feature is demonstration of communication
between the cystic lesion and the pancreatic duct (Fig. 7)
[26]. This is seen in only 18% on CT compared with 73%
using MRI [25]. Additionally, MRI has proved superior at
differentiating IPMN from other cystic tumours [27].
Bulging of the duodenal papilla into the lumen of the
duodenum is also virtually diagnostic of IPMN [28]. The
pancreatic parenchyma tends to be atrophic from mucinous
obstruction. The tumour is usually not seen itself, but its
presence is inferred from the sequelae of its pronounced
mucin production (Fig. 8).
Fig. 7 a Arterial phase CT in a 59-year-old man showing a lobulated
cystic mass (short arrow) shown to be a side branch IPMN. Note
pancreatic duct (long arrow). b Coronal reformat in the same patient
showing the lobulated IPMN (short arrow) extending to the pancreatic
duct (long arrow) via a short side branch (arrowhead). c Axial CT
showing a lobulated cystic side branch IPMN in a 66-year-old woman
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well as focal or diffuse disease:
1. Main duct type—moderate or marked dilatation of the
main pancreatic duct
2. Segmental—can occur in the body or tail with upstream
dilatation of the duct only
3. Branch duct type—most frequently in the uncinate
process and appears as round or oval lobulated masses
4. Diffuse type—homogeneous low density appearance
and differentiation from chronic pancreatitis can be
difficult
Mural nodules help support the diagnosis.
Although frequently benign, they may contain carcinoma
in situ or be frankly malignant with features of malignant
degeneration including irregularity of the wall and thick septa
with solid nodules [28]. Similar to mucinous cystic neo-
plasms, IPMN cyst fluid analysis shows high CEA and CA
72–4. A point of difference is high amylase in IPMN [18].
Elevated serum CEA and CA 125 are also associated with
malignant lesions [18]. The best predictor of malignant
potential, however, is tumour location, with the main duct
type having a 70% chance of harbouring malignancy
compared with 25% for the branch duct type [29]. All main
duct type IPMN are recommended for resection, whereas
branch duct type IPMN less than 3 cm in size and lacking
mural nodules could potentially be managed conservatively
[18].
Solid pseudopapillary neoplasm (SPPN)
Also sometimes referred to as solid pseudopapillary
tumours (SPT), solid and papillary epithelial neoplasms
(SPEN), or Frantz’s tumours, these tumours occur in young
women in the 2nd and 3rd decades of life (the ‘daughter’
tumour), and are of fairly low malignant potential [30].
Metastases or vascular invasion may complicate 10–15% of
cases; however, long-term survival is common in these
patients following surgery and chemotherapy [31]. Com-
plete surgical excision is always recommended, not only
because of malignant potential but also because of the
considerable size to which these tumours can grow. SPPNs
begin as solid masses with a delicate internal vasculature.
As the lesion enlarges, haemorrhagic and cystic degenera-
Fig. 8 Grossly distended main pancreatic duct (arrow) in an 83-year-
old man with a main duct IPMN
Fig. 9 a Portal venous phase CT with a solid and papillary tumour
replacing the pancreatic tail in a 27-year-old woman. Note internal
septations (short arrow), solid elements (arrow head) and peripheral
calcification (long arrow). b Portal venous CT of a large heterogenous
mass replacing the pancreatic head in a 19 year-old woman. Note the
predominantly cystic density with irregular internal enhancing septations
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remaining intact [32].
The typical appearance is of a large, mixed solid and
cystic lesion that occurs most commonly in the head or tail
of the pancreas [33]. SPPNs tend to be well-encapsulated
and contain haemorrhagic components, with more solid
enhancing areas at the periphery and enhancement of the
cyst wall [34]. Internal fluid–debris levels may be present
and peripheral calcification can occur (Fig. 9)[ 32]. Despite
their large size, they typically produce only minor dilatation
of the pancreatic duct and no biliary distension [35].
Invasion of surrounding structures is also rare.
Neuroendocrine tumours
Neuroendocrine tumours, or islet cell tumours, account for
1–5% of all pancreatic neoplasms and arise from the
endocrine pancreas [36]. Patients are typically in their
50s, with a slight male predominance. Most are solitary
lesions that arise sporadically, but neuroendocrine tumours
may also occur as part of genetic syndromes, such as
multiple endocrine neoplasia type 1 (MEN 1), von Hippel-
Lindau, neurofibromatosis type 1 and tuberous sclerosis.
Neoplasms in these conditions are often multiple, particu-
larly in MEN 1.
Islet cell tumours are also classified as functional and
non-functional, depending on whether the cells actively
secrete hormones. The functional lesions present with
classic clinical syndromes, depending on the cell type,
and tend to be less than 3 cm in size at diagnosis because of
systemic symptoms leading to presentation, while non-
functioning tumours are more likely to present with
symptoms of mass effect [37, 38]. Functional tumours
include insulinomas (present with hypoglycaemia) and
gastrinomas (present with peptic ulcer disease in
Zollinger-Ellison Syndrome, and typically arise in the
gastrinoma triangle bounded by the junction of the cystic
Fig. 10 a Arterially enhancing soft tissue insulinoma (arrow) in a 75-
year-old woman with hypoglycaemia. b, Axial arterial CT showing an
arterially enhancing insulinoma in the uncinated process in a 76-year-
old man. c Coronal section in the same patient as figure 10b, showing
the enhancing insulinoma (arrow)
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pancreas, and the junction of the second and third portions
of the duodenum), glucagonomas (present with diabetes,
anaemia, weight loss and rash), VIPomas (presents with
WDHA syndrome (watery diarrhoea, hypokalaemia, achlor-
hydria) and somatostatinomas (present with diabetes,
cholelithiasis and steatorrhoea).
In general, islet cell tumours are hyperenhancing and
may be within the gland or exophytic [39] (Fig. 10). These
l e s i o n sl a c kt h ed e s m o p l a s t i cr e a c t i o ns e e ni nd u c t a l
adenocarcinoma and so rarely cause pancreatic duct
dilatation or obstruction [36]. In a review of 1,483
pancreatic neuroendocrine tumours, 91% were non-
functioning, 2.5% were insulinomas, 4.2% gastrinomas,
1.6% glucagonomas and 0.9% VIPoma [37]. Overall, 60%
were metastatic and 21% were locally advanced with no
difference between functioning and non-functioning tumour
groups. The most useful discriminator of malignant risk is
tumour size with 90% of tumours under 20 mm being
benign and 71% over 20 mm being malignant [40].
Neuroendocrine lesions do not characteristically show
calcification and as lesions grow they develop cystic or
necrotic areas. The periphery of the lesion will continue
to arterially enhance [36]. Local vascular encasement or
invasion, which is commonly seen with ductal adenocar-
cinoma, is rarely seen with neuroendocrine tumours [36].
Arterial phase imaging of the liver is vital to detect hepatic
metastases.
Pancreatic lymphoma
Primary lymphoma of the pancreas is rare. Secondary
involvement can occur via direct extension from the
retroperitoneum. Symptoms are typical of those of systemic
lymphoma and jaundice is rare, even with large masses at
the pancreatic head.
Most pancreatic lymphomas are homogeneous, low
attenuation masses. They tend to poorly enhance, but
enhancement will also be homogeneous [41]. Morpholog-
ical patterns are focal and diffuse. The focal type is
distinguished from ductal adenocarcinoma by the lack of
pancreatic duct dilatation. This tends to be mild and occurs
late [41]. Lymphoma may encase vessels, but exerts little
mass effect and unlike adenocarcinoma does not typically
invade vessels or produce thrombosis (Fig. 11). Lymph-
adenopathy below the renal vein level is strongly support-
ive of a diagnosis of lymphoma [42]. The diffuse type can
mimic acute pancreatitis with global gland enlargement;
however, it should be clinically distinguishable. Calcifica-
tion should not be present in primary pancreatic lymphoma
and this may also be a key feature in diagnostic imaging
[42].
Fig. 12 Arterial phase CT in a 60-year-old woman showing
innumerable hypervascular pancreatic renal cell carcinoma metastases
(short arrows). Note nephrectomy clips (long arrow)
Fig. 11 a Homogeneous large lymphomatous soft tissue mass
(arrowheads) encasing vessels in a 72-year-old man and replacing
the head of the pancreas, with normal body and tail (arrow). b Subtle
low density nodule (arrow) in the head of the pancreas in a 33-year-
old with diffuse large B cell lymphoma resolved with treatment and
was presumed lymphomatous involvement
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Metastases to the pancreas are rare, found in only 3–12% of
patients at autopsy with advanced malignancy [43]. The
most frequent primary lesions are bronchogenic carcinoma
and renal cell carcinoma. Other documented sources are
breast, thyroid, melanoma, gastrointestinal tract and hepa-
tocellular carcinoma [43].
Patterns of metastatic deposits include a single focal
mass (most common), diffuse gland enlargement and
multiple pancreatic nodules (Fig. 12). Lesions are usually
hypodense to pancreas and can show the enhancement
pattern of the primary lesion. Both renal cell carcinoma and
bronchogenic carcinoma tend to result in arterially enhanc-
ing metastases, while a peripheral rim of enhancement may
be seen with other primaries [43]. The diffuse form tends to
be isodense to pancreas post-contrast medium administra-
tion but may show low attenuation areas centrally [44].
Conclusion
As demonstrated, the spectrum of pancreatic neoplasms has
varying age and gender profiles as well as clinical
presentations. This information, coupled with knowledge
of the typical CT characteristics, allows for reasonable
confidence in diagnosis. Multiphase CT, with the range of
post-processing techniques available, also plays a crucial
role in determining the resectability of pancreatic ductal
adenocarcinoma, the most common pancreatic neoplasm.
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